アジア太平洋地域の連続バイオプロセス市場：用途・エンドユーザー・製品・国別の分析・予測 (2023-2033年)

アジア太平洋地域の連続バイオプロセスの市場規模は、2023年の5,100万米ドルから、予測期間中はCAGR 22.50%で推移し、2033年には3億8,850万米ドルの規模に成長すると予測されています。

歩留まり、柔軟性、製造性、製品の一貫性を向上させ、同時に製造コストを下げることでバイオ医薬品製造を改善したいという需要の高まりが同市場を牽引しています。一貫した結果を出すために、バイオプロセスは近年、連続モードへと移行しています。

アジア太平洋地域の連続バイオプロセス市場は、世界のバイオ医薬品分野で極めて重要な役割を担うようになり、急速に拡大しています。生産性、適応性、製品品質の向上が重視される中、連続バイオプロセスはアジア太平洋地域のバイオ製造業を変える戦略として認識されつつあります。収率の向上、製造コストの削減、信頼性の高い高品質製品の製造能力など、多くの利点があるため、この地域で事業を展開するバイオ医薬品企業にとって、この戦略は望ましいものとなっています。

この地域の強力なバイオ医薬品製造インフラと新規治療に対する需要の高まりにより、同地域では連続上流バイオプロセスの採用が広がっています。現在重視されているのは、連続下流バイオプロセスを統合し、プロセス全体の効率を最適化し、オペレーションをさらに合理化することです。最初から最後までシームレスな製造フロー、ダウンタイムの減少、バイオ医薬品製造のスケーラビリティの向上により、この統合はゲームチェンジャーになると予測されています。

バイオプロセス技術の継続的発展は、この地域のR&Dへの多額の投資と政府の奨励策によって促進されています。アジア太平洋地域のバイオ医薬品市場が成長するにつれて、連続バイオプロセスの採用は加速し、同地域は最先端のバイオ製造技術のパイオニアとしての地位を確立すると予想されています。

市場の分類

セグメンテーション1：製品別

• クロマトグラフィシステム・消耗品
• ろ過システム・装置
• バイオリアクター
• 細胞培養培地・細胞株・バッファ・試薬
• その他

セグメンテーション2：用途別

• モノクローナル抗体
• ワクチン
• 細胞・遺伝子治療
• その他

セグメンテーション3：エンドユーザー別

• 製薬会社・バイオテクノロジー企業
• 学術・研究機関
• CRO

セグメンテーション4：国別

• 日本
• インド
• 中国
• 韓国
• オーストラリア
• その他

当レポートでは、アジア太平洋地域の連続バイオプロセスの市場を調査し、業界の動向、技術・特許の動向、法規制環境、市場成長促進要因・抑制要因、市場規模の推移・予測、各種区分・主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

第1章 市場

• 動向：現在および将来の影響評価
  • 連続バイオプロセス市場：動向分析
  • バイオ医薬品業界による連続バイオプロセスのデジタル化
  • 使い捨てバイオプロセス機器の使用増加
• サプライチェーンの概要
  • バリューチェーン分析
• R&Dレビュー
  • 特許出願動向（国・年別）
• 規制状況
• 主要イベントの影響分析：COVID-19
• 市場力学：概要
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第2章 地域

• 地域別概要
• アジア太平洋
  • 地域概要
  • 市場成長推進因子
  • 市場課題
  • 用途
  • 製品
  • 中国
  • 用途
  • 製品
  • インド
  • 用途
  • 製品
  • オーストラリア
  • 用途
  • 製品
  • 日本
  • 用途
  • 製品
  • 韓国
  • 用途
  • 製品
  • その他
  • 用途
  • 製品

第3章 市場：競合ベンチマーキングと企業プロファイル

• 次なるフロンティア
• 地理的評価
  • OmniBRx Biotechnologies Pvt Ltd.

第4章 調査手法

List of Figures

• Figure 1: Asia-Pacific Continuous Bioprocessing Market, $Million, 2023, 2026, and 2033
• Figure 2: Asia-Pacific Continuous Bioprocessing Market (by Application), $Million, 2022, 2026, and 2033
• Figure 3: Asia-Pacific Continuous Bioprocessing Market (by Product), $Million, 2022, 2026, and 2033
• Figure 4: Asia-Pacific Continuous Bioprocessing Market (by End User), $Million, 2022, 2026, and 2033
• Figure 5: Evolution of Single-Use Facilities, 2019-2022
• Figure 6: Supply Chain and Identifying Risks within the Supply Chain
• Figure 7: Continuous Bioprocessing Market (by Country), January 2020-December 2023
• Figure 8: Continuous Bioprocessing Market (by Year), January 2020-December 2023
• Figure 9: Long-Term Effect of COVID-19 on Bioprocessing, Biopharma Vs Suppliers
• Figure 10: Impact of COVID-19 on the Continuous Bioprocessing Market, Pre, During, and Post-COVID-19 Scenario
• Figure 11: Impact Analysis of Market Navigating Factors, 2023-2033
• Figure 12: Growth of Biopharmaceutical Research and Development, 2012-2022, $ Million
• Figure 13: Comparison of Processes and Facilities for Different Batch Types
• Figure 14: Cost Comparison: Continuous vs. Batch and Fed-Batch Bioprocessing, $ Million
• Figure 15: Respondents Using Single-Use Bioprocessing Technology, All Scales (R&D to Commercial), 2018-2022, %
• Figure 16: Novel Bioprocessing Systems/Innovations Evaluated in 12 Months, 2021
• Figure 17: Factors Contributing to High Initial Costs in Continuous Bioprocessing Facilities
• Figure 18: Proposed Technologies in Continuous Biopharmaceutical Manufacturing
• Figure 19: Developments in Continuous Bioprocessing Generating Need for End-to-End Continuous Bioprocessing Facilities
• Figure 20: China Continuous Bioprocessing Market, $Million, 2022-2033
• Figure 21: India Continuous Bioprocessing Market, $Million, 2022-2033
• Figure 22: Australia Continuous Bioprocessing Market, $Million, 2022-2033
• Figure 23: Japan Continuous Bioprocessing Market, $Million, 2022-2033
• Figure 24: South Korea Continuous Bioprocessing Market, $Million, 2022-2033
• Figure 25: Rest-of-Asia-Pacific Continuous Bioprocessing Market, $Million, 2022-2033
• Figure 26: Strategic Initiatives, 2020-2023
• Figure 27: Share of Strategic Initiatives, 2020-2023
• Figure 28: Data Triangulation
• Figure 29: Top-Down and Bottom-Up Approach
• Figure 30: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Continuous Bioprocessing Market, Opportunities
• Table 3: Product Portfolio Company Positioning
• Table 4: Example of Digitization of Continuous Bioprocessing
• Table 5: Survey on Industry Perceptions of Continuous Bioprocessing Vs Batch-Fed Processing (N=140+ Biopharmaceutical Companies)
• Table 6: Continuous Bioprocessing Market (by Region), $Million, 2022-2033
• Table 7: Asia-Pacific Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 8: Asia-Pacific Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 9: Asia-Pacific Continuous Bioprocessing Market (by Product), $Million, 2022-2033
• Table 10: China Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 11: China Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 12: China Continuous Bioprocessing Market (by Product), $Million, 2022-2033
• Table 13: India Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 14: India Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 15: India Continuous Bioprocessing Market (by Product), $Million, 2022-2033
• Table 16: Australia Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 17: Australia Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 18: Australia Continuous Bioprocessing Market (by Product), $Million, 2022-2033
• Table 19: Japan Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 20: Japan Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 21: Japan Continuous Bioprocessing Market (by Product), $Million, 2022-2033
• Table 22: South Korea Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 23: South Korea Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 24: South Korea Continuous Bioprocessing Market (by Product), $Million, 2022-2033
• Table 25: Rest-of-Asia-Pacific Continuous Bioprocessing Market (by Application), $Million, 2022-2033
• Table 26: Rest-of-Asia-Pacific Continuous Bioprocessing Market (by End User), $Million, 2022-2033
• Table 27: Rest-of-Asia-Pacific Continuous Bioprocessing Market (by Product), $Million, 2022-2033

Introduction to Asia-Pacific (APAC) Continuous Bioprocessing Market

The Asia-Pacific continuous bioprocessing market was valued at $51.0 million in 2023 and is expected to reach $388.5 million by 2033, growing at a CAGR of 22.50% between 2023 and 2033. Increased demand to improve biopharmaceutical production through increased yield, flexibility, productivity, and product consistency at the same time as lower manufacturing costs is driving the APAC market for continuous bioprocessing. In order to produce consistent results, bioprocessing has been moving toward continuous mode in recent years. The goal of ongoing efforts is to integrate downstream bioprocessing into a continuous operation, thereby increasing the efficiency and capabilities of the industry, even though continuous upstream bioprocessing has been established and widely adopted.

Market Introduction

The Asia-Pacific continuous bioprocessing market is expanding quickly as the area assumes a pivotal role in the worldwide biopharmaceutical sector. As the emphasis on improving productivity, adaptability, and product quality grows, continuous bioprocessing is becoming recognized as a game-changing strategy for biomanufacturing in the Asia-Pacific region. Many benefits, such as increased yields, lower manufacturing costs, and the capacity to produce reliable, high-quality products, make this strategy a desirable one for biopharmaceutical companies operating in the area.

The region's strong biopharmaceutical manufacturing infrastructure and the rising demand for novel therapies have led to the widespread adoption of continuous upstream bioprocessing in APAC. The emphasis now is on integrating continuous downstream bioprocessing, optimizing overall process efficiency, and further streamlining operations. With seamless production flows from beginning to end, decreased downtime, and improved scalability of biopharmaceutical production, this integration is predicted to be a game-changer.

The continuous development of bioprocessing technologies is being fueled by the region's substantial investment in research and development as well as encouraging government initiatives. Continuous bioprocessing adoption is expected to pick up speed as the APAC biopharmaceutical market grows, establishing the region as a pioneer in cutting-edge biomanufacturing techniques.

Market Segmentation

Segmentation 1: by Product

• Chromatography Systems and Consumables
• Filtration Systems and Devices
• Bioreactors
• Cell Culture Media, Cell Lines, Buffers, and Reagents
• Other Products

Segmentation 2: by Application

• Monoclonal Antibodies
• Vaccines
• Cell and Gene Therapy
• Other Applications

Segmentation 3: by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

Segmentation 4: by Country

• Japan
• India
• China
• South Korea
• Australia
• Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific continuous bioprocessing market has been segmented based on application, end user, and product. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: In the continuous bioprocessing market, competitive strategy centers around innovation, collaboration, customization, and sustainability. Companies in the market strive to innovate by developing more efficient, scalable, and flexible bioprocessing technologies that reduce production times and costs while maintaining high product quality. Collaboration between equipment manufacturers, biopharmaceutical companies, and research institutions is crucial for sharing knowledge, optimizing processes, and accelerating the adoption of continuous bioprocessing.

Table of Contents

Executive Summary

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Continuous Bioprocessing Market Trend Analysis
  • 1.1.2 Digitization of Continuous Bioprocessing by the Biopharmaceutical Industry
  • 1.1.3 Increasing Use of Single-Use or Disposable Bioprocessing Equipment
• 1.2 Supply Chain Overview
  • 1.2.1 Value Chain Analysis
• 1.3 Research and Development Review
  • 1.3.1 Patent Filing Trend (by Country, by Year)
• 1.4 Regulatory Landscape
• 1.5 Impact Analysis for Key Events: COVID-19
• 1.6 Market Dynamics Overview
  • 1.6.1 Market Drivers
    • 1.6.1.1 Growing Demand for Continuous Bioprocessing due to the Flourishing Biopharmaceutical Sector
    • 1.6.1.2 Cost Reduction with Continuous Bioprocessing as Compared to Batch and Fed-Batch Bioprocessing
    • 1.6.1.3 Increasing Adoption of New Technologies like Single-Use Bioprocessing Technology
  • 1.6.2 Market Restraints
    • 1.6.2.1 Technological Complexities and Operational Challenges
    • 1.6.2.2 High Initial Cost Associated with Continuous Bioprocessing
  • 1.6.3 Market Opportunities
    • 1.6.3.1 Numerous Proposed Technologies in Continuous Bioprocessing
    • 1.6.3.2 Moving Closer to End-to-End Continuous Bioprocessing

2 Region

• 2.1 Regional Summary
• 2.2 Asia-Pacific
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Application
  • 2.2.5 Product
  • 2.2.6 China
  • 2.2.7 Application
  • 2.2.8 Product
  • 2.2.9 India
  • 2.2.10 Application
  • 2.2.11 Product
  • 2.2.12 Australia
  • 2.2.13 Application
  • 2.2.14 Product
  • 2.2.15 Japan
  • 2.2.16 Application
  • 2.2.17 Product
  • 2.2.18 South Korea
  • 2.2.19 Application
  • 2.2.20 Product
  • 2.2.21 Rest-of-Asia-Pacific
  • 2.2.22 Application
  • 2.2.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Next Frontiers
• 3.2 Geographic Assessment
  • 3.2.1 OmniBRx Biotechnologies Pvt Ltd.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products/Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast